Study: CBD Shows Potent Antibacterial Activity Against Drug-Resistant Enterococcus Strains

OG article by Anthony Martinelli

January 15, 2026

A laboratory study published in the journal Molecules demonstrates that cannabidiol (CBD) possesses potent antibacterial activity against drug-resistant strains of Enterococcus bacteria. Researchers from Nicolaus Copernicus University and Wrocław University of Environmental and Life Sciences evaluated five commercial CBD oil products alongside 99% pure CBD crystals against 20 clinical isolates of Enterococcus faecalis and Enterococcus faecium using microdilution assays to determine minimal inhibitory concentrations (MICs). CBD consistently inhibited bacterial growth, with MIC values at or below 1 μg/mL for all tested strains. Higher concentrations produced more pronounced effects, and pure CBD crystals proved especially effective against E. faecium compared to E. faecalis. These results position CBD as a promising candidate for addressing antibiotic-resistant infections in clinical settings, particularly where Enterococcus poses significant challenges in healthcare environments. While the mechanisms remain under investigation, the findings underscore CBD's potential therapeutic role against multidrug-resistant pathogens. Further in vivo studies are needed to confirm efficacy and safety for practical applications.